Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18513030 | 0.98 | MEN1 (0.71) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7750774 | 0.92 | MEN1 (0.67) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL9259257 | 0.85 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21765846 | 0.85 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11758762 | 0.85 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25475907 | 0.84 | MEN1 (0.45) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22664245 | 0.84 | CASP2 (0.52) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL22664218 | 0.84 | MEN1 (0.45) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21016186 | 0.84 | MEN1 (0.45) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24193577 | 0.84 | MEN1 (0.45) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | MEN1 3624/4885KMT2A 2372/4885CASP2 3605/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | MEN1 2766/4885KMT2A 1237/4885CASP2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.